September 29, 2020 — Cepheid today announced it has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA) for Xpert® Xpress SARS-CoV-2/Flu/RSV, a rapid molecular diagnostic test for the qualitative detection of the viruses causing COVID-19, Flu A, Flu B, and RSV infections from a single patient sample. The four-in-one test is designed for use on any of Cepheid’s over 26,000 GeneXpert® Systems placed worldwide, with results delivered in approximately 36 minutes. #Cepheid #moleculardiagnostics
Visit www.cepheid.com/coronavirus for more information.
Ещё видео!